Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Carcinoma, Non-Small-Cell Lung 481Neoplasms 294Breast Neoplasms 282Colorectal Neoplasms 225Neoplasm Metastasis 191Prostatic Neoplasms 172Ovarian Neoplasms 165Lung Neoplasms 155Multiple Myeloma 153Recurrence 133Melanoma 117Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 105Stomach Neoplasms 98Endometrial Neoplasms 98Leukemia, Myeloid, Acute 96Small Cell Lung Carcinoma 85Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 82Triple Negative Breast Neoplasms 81Carcinoma, Renal Cell 81Carcinoma, Hepatocellular 80Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 73Lymphoma, Follicular 67Advanced Solid Tumors 64Lymphoma 62Glioblastoma 60Parkinson Disease 4, Autosomal Dominant Lewy Body 56Head and Neck Neoplasms 54

Interventions

nilotinib 2asciminib 2bosutinib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Philadelphia Chromosome × 90 days × Clear all
NCT04971226 2026-06-08

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡